acitretin / Generic mfg. - LARVOL DELTA

SG05 The use of oral methotrexate in a case of Ferguson-Smith syndrome. (PubMed, Br J Dermatol) - "Despite 3 years of acitretin therapy, surgical excisions, imiquimod and repeated cryotherapy, the lesions remained poorly controlled. This case, along with her sister's experience, highlights oral methotrexate as a potential therapeutic option for refractory cases. Further studies are needed to explore its role in the management of this challenging condition."

Journal • Brain Cancer • Dermatology • Immunology • Inflammatory Arthritis • Neuralgia • Oncology • Ophthalmology • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Solid Tumor • TGFBR1

P086 Management of severe psoriasis in patients with concomitant malignancy: a retrospective observational study. (PubMed, Br J Dermatol) - "Prior psoriasis treatments included ultraviolet B phototherapy, methotrexate, ciclosporin and acitretin. At cancer diagnosis, 10 patients (20%) were on tumour necrosis factor (TNF)-α inhibitors, 8 (16%) on interleukin (IL)-17 inhibitors, five (10%) on IL-12/23 inhibitors, 5 (10%) on IL-23 inhibitors, 6 (12%) on methotrexate, 2 (4%) on apremilast and 1 (2%) on ciclosporin...Multidisciplinary collaboration and shared decision making are essential. Clinicians should consider biologic therapies for patients with both malignancy and uncontrolled psoriasis, tailoring treatments to patient-specific factors and malignancy type."

Journal • Observational data • Retrospective data • Breast Cancer • Colon Cancer • Colorectal Cancer • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Psoriasis • Rectal Cancer • Solid Tumor • IL12A • IL17A • IL23A

BI18 Skin conditions in immunocompromised individuals: a service evaluation. (PubMed, Br J Dermatol) - "Tacrolimus, mycophenolate mofetil and prednisolone accounted for 76% of all immunosuppressive medications prescribed...For patients at high risk of further keratinocyte carcinomas, only 42% were receiving chemoprevention with acitretin or nicotinamide. There were 45 recurrences of squamous cell carcinoma (SCC) and basal cell carcinoma, and seven patients required treatment for metastatic SCC or sarcomatoid carcinoma - these were managed with cemiplimab, radiotherapy and surgical excision...Severe inflammatory conditions and a range of undiagnosed cutaneous lesions add to the complex dermatological burden in this population. Multidisciplinary collaboration between dermatology, transplant and haematology teams remains crucial to optimizing outcomes for these patients."

Journal • Retrospective data • Atopic Dermatitis • Basal Cell Carcinoma • Dermatitis • Dermatology • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Melanoma • Non-melanoma Skin Cancer • Oncology • Rheumatology • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Transplantation

PA15 Harlequin ichthyosis: a multidisciplinary journey from antenatal to neonatal care. (PubMed, Br J Dermatol) - "Dermatologists commenced oral acitretin at 0.5 mg kg-1 per day at 2 days of life, increasing to 1 mg kg-1 per day on day 30...Several expert centres provide support upon request. We hope that this case will add to the impetus for a national MDT framework for congenital ichthyosis to standardize care, ensure equitable access to specialized services, establish a national register and provide dedicated nursing support to improve patient outcomes."

Journal • Atopic Dermatitis • Dermatology • Hematological Disorders • Immunology • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology • Otorhinolaryngology • Septic Shock • Transplantation • Vitiligo • ABCA1

SG14 Homozygous pathogenic variant in transgradient palmoplantar keratoderma: causative, contributory or irrelevant? (PubMed, Br J Dermatol) - "He is currently managed on acitretin 25 mg once daily and psoralen plus ultraviolet A. Acitretin at 50 mg alone was effective but was discontinued due to side-effects. Previous treatment with secukinumab and adalimumab was not beneficial...However, 10% of individuals with European ancestry are heterozygous carriers of loss-of-function variants in the FLG gene. This high carrier frequency in the general population suggests that FLG may be only a contributing factor, and other variants or environmental factors are important in the manifestation of PPK, if FLG variants are found in so many unaffected individuals."

Journal • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases • Vitiligo • FLG

O07 Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (PubMed, Br J Dermatol) - "Inclusion criteria were adults who received at least one of the biologics, apremilast or conventional nonbiologics (acitretin, ciclosporin and methotrexate) for ≥ 6 months. All biologics licensed for psoriasis were analysed except for infliximab, which had higher prescription criteria...The certolizumab group had a low mean age of 37.4 years (SD 10.3), the ustekinumab group had a significantly longer median treatment duration of over 4 years (IQR 1.83-6.73), and more patients in the ixekizumab (42.6%) and certolizumab (40.6%) groups had concomitant psoriatic arthritis...IRs (95% CIs) of other tumour necrosis factor-α inhibitors were 15.7 (14.5-17.1) for adalimumab and 16.7 (13.8-20.0) for etanercept. For interleukin-17 inhibitors the IRs (95% CIs) were 18.4 (15.9-21.2) for secukinumab, 7.63 (0.92-27.6) for bimekizumab, 14.5 (7.73-24.8) for brodalumab and 18.5 (14.0-24.0) for ixekizumab. For interleukin-23 inhibitors the IRs (95% CIs) were 13.5 (9.97-17.8) for guselkumab,..."

Journal • Observational data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

SG01 Naltrexone: not a one-trick pony for opioid overdose. The use of naltrexone to successfully treat severe Hailey-Hailey disease. (PubMed, Br J Dermatol) - "In 2022, acitretin was commenced and uptitrated to 25 mg once daily...Other immunosuppressive agents such as methotrexate, ciclosporin and azathioprine have been described in the literature with varying efficacy...Naltrexone is postulated to work due to analgesic and anti-inflammatory effects. It is a well-tolerated treatment for severe HHD that has drastically improved both our patient's skin and his quality of life."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Dermatology • Genetic Disorders • Oncology • Pain • IL6 • TLR4

BI16 The COAST (Contemporary Outcomes After cutaneous SCC in Transplant recipients) study: final results and implications for management following the first cutaneous squamous cell carcinoma in kidney transplant recipients. (PubMed, Br J Dermatol) - "Within 6 months of the first cSCC, 21% of KTRs were using topical chemoprevention (mainly 5-fluorouracil cream), 6% started systemic chemoprevention (acitretin or nicotinamide) and 5% used destructive therapies...Immunosuppression reduction strategies varied both within and between centres and were more frequently undertaken in patients with high-risk CSCC or in those on azathioprine (P = 0.01)...These data highlight the urgent need for prospective studies to identify optimal management of KTR following a first cSCC. Here we propose a risk stratification approach that may be used to guide prevention strategies."

Journal • Retrospective data • Dermatology • Non-melanoma Skin Cancer • Oncology • Solid Organ Transplantation • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Transplantation

P048 Lenalidomide use in recalcitrant inflammatory dermatoses: a trio of successes. (PubMed, Br J Dermatol) - "A 36-year-old woman with recurrent aphthous stomatitis had not responded to treatment with colchicine, pentoxifylline, azathioprine, dapsone or mycophenolate mofetil...A 49-year-old woman with severe recalcitrant cutaneous discoid lupus erythematosus (CDLE), systemic lupus and Raynaud phenomenon with chilblains had not responded to, had intolerance to or had adverse side-effects with multiple systemic agents including hydroxychloroquine, mepacrine, dapsone, rituximab biosimilar, mycophenolate mofetil, fumaric acid esters, acitretin, ciclosporin, thalidomide (tremor/loss of concentration), belimumab and methotrexate...Baseline and renal function monitoring is required for dose adjustment, and strict adherence to pregnancy prevention programmes is necessitated due to teratogenicity. Our three cases demonstrate lenalidomide to be a clinically beneficial, fast-acting and well-tolerated alternative off-label option for recalcitrant inflammatory dermatoses."

Journal • Cardiovascular • Cataract • Dental Disorders • Dermatology • Discoid Lupus Erythematosus • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Movement Disorders • Multiple Myeloma • Myelodysplastic Syndrome • Neutropenia • Oncology • Ophthalmology • Pain • Peripheral Neuropathic Pain • Rheumatology • Stomatitis • Systemic Lupus Erythematosus • Thrombocytopenia • IL12A • IL6

BI21 Intermittent and progressive pustular psoriasis during chemotherapy cycles in a toddler. (PubMed, Br J Dermatol) - "Just before his next chemotherapy cycle (cisplatin and etoposide), the rash recurred as a pruritic pustular eruption across the frontal and retroauricular scalp; skin biopsy suggested nonspecific subacute eczematous dermatitis...Topical ivermectin and ketoconazole did not help...A second biopsy was taken due to clinical suspicion of psoriasis, and 10 days of oral prednisolone was given to try to clear his skin for autologous stem cell transplantation (HSCT)...He was treated with topical calcipotriol and mometasone 0.1%, with consideration of acitretin should he not improve. Fortunately, the rash settled with topical therapy and time. After completing proton radiotherapy prior to tumour resection, he had six cycles of maintenance immunotherapy (dinutuximab) with no recurrence of the rash, despite monthly GCSF, and good cell counts, and has now completed his oncological therapy."

Journal • Atopic Dermatitis • Bone Marrow Transplantation • Contact Dermatitis • Dermatitis • Dermatology • Epstein-Barr Virus Infections • Herpes Simplex • Herpes Zoster • Immunology • Neuroblastoma • Oncology • Psoriasis • Pustular Psoriasis • Solid Tumor • Transplantation • Varicella Zoster

P099 Spesolimab use in effective treatment of generalized pustular psoriasis: a case report. (PubMed, Br J Dermatol) - "He was managed as an inpatient with topical treatment and oral prednisolone...He received oral methotrexate therapy but upon readmission with pustulation flare, diagnosis of GPP was confirmed and acitretin commenced...The patient then experienced widespread desquamative eruption and incipient pustulation, and as it was not possible to secure further compassionate funding for spesolimab as maintenance therapy, he commenced secukinumab therapy...In our patient with GPP spesolimab was a highly effective treatment modality, leading to lasting skin clearance when used as monotherapy from its induction, but unavailable for maintenance therapy. We await NICE appraisal, due March 2025, to consider its use within NHS care."

Journal • Dermatology • Gastroenterology • Hepatology • Immunology • Keratitis • Pancreatitis • Psoriasis • Pustular Psoriasis

BI07 (P086) Management of severe psoriasis in patients with concomitant malignancy: a retrospective observational study. (PubMed, Br J Dermatol) - "Prior psoriasis treatments included ultraviolet B phototherapy, methotrexate, ciclosporin and acitretin. At cancer diagnosis, 10 patients (20%) were on tumour necrosis factor (TNF)-α inhibitors, eight (16%) on interleukin (IL)-17 inhibitors, five (10%) on IL-12/23 inhibitors, five (10%) on IL-23 inhibitors, six (12%) on methotrexate, two (4%) on apremilast and one (2%) on ciclosporin...Multidisciplinary collaboration and shared decision making are essential. Clinicians should consider biologic therapies for patients with both malignancy and uncontrolled psoriasis, tailoring treatments to patient-specific factors and malignancy type."

Journal • Observational data • Retrospective data • Breast Cancer • Colon Cancer • Colorectal Cancer • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Psoriasis • Rectal Cancer • Solid Tumor • IL12A • IL17A • IL23A

DP10 Are all Sweet's Sweet? (PubMed, Br J Dermatol) - "Our patient was started on topical steroids, a tapering dose of oral steroids and acitretin, following which the rash has improved...While each condition has been individually documented in the literature, their concurrent occurrence in a single patient is exceptionally rare and raises questions about potential shared immunological and molecular pathways. This case represents the first documented instance of the coexistence of NDDH and PPP, underscoring the necessity for a high index of suspicion and a comprehensive diagnostic evaluation when faced with atypical or overlapping inflammatory dermatoses."

Journal • Dermatology • Immunology • Psoriasis • Vasculitis • CRP

Sequential Treatment of Generalized Pustular Psoriasis Combined with Bullous Pemphigoid Using Spesolimab and Dupilumab: A Case Report and Literature Review. (PubMed, Case Rep Dermatol) - "Initial acitretin therapy resolved pustules but not bullae. This case highlights the potential of sequential spesolimab and dupilumab therapy as an effective and safe approach for managing GPP coexisting with BP. Targeting distinct inflammatory pathways may provide a new treatment option for complex dermatological comorbidities."

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Inflammation • Psoriasis • Pustular Psoriasis • IL13 • IL4

A Case of Generalized Bowen's Disease Accompanied by Generalized Seborrheic Keratosis with Literature Review. (PubMed, Case Rep Dermatol) - "Treatment included cryotherapy, oral acitretin capsules, and topical isotretinoin cream. Clinicians should maintain a high index of suspicion when evaluating irritated or inflamed SK lesions, as they may mask underlying Bowen's-like changes. Early recognition and appropriate management are essential to ensure optimal patient outcomes."

Journal • Bowens Disease • Oncology

Grenz Ray Therapy for Porokeratosis Ptychotropica: A Case Report. (PubMed, Case Rep Dermatol) - "She was previously unsuccessfully treated with topical, intralesional and oral corticosteroids, topical vitamin D analogues, topical simvastatin-cholesterol cream, topical fluorouracil cream, acitretin, and CO2 laser assisted photodynamic therapy. This is the first reported case of PP being treated with Grenz rays. With no effective treatment, Grenz therapy may present a potential effective treatment for some patients."

Journal

Diagnosis of Castleman Disease in a Patient with Erythrodermic Psoriasis (ISDS 2025) - "Clinical assessment suggested erythroderma or exfoliative dermatitis, leading to the reinstatement of therapy with acitretin and topical corticosteroids...She was referred to the hematology department and ultimately diagnosed with iMCD upon admission. This case underscores the rare coexistence of erythrodermic psoriasis and iMCD."

Clinical • Dermatitis • Dermatology • Dermatopathology • Hematological Disorders • Immunology • Psoriasis • Rare Diseases

Comparing the effectiveness and drug persistence of methotrexate, cyclosporine, and acitretin for psoriasis. (PubMed, Int J Womens Dermatol) - "Methotrexate is typically the first-line systemic therapy in Thailand, which may underestimate the true efficacy of cyclosporine and acitretin when used subsequently. Methotrexate was more effective and persistent than were cyclosporine and acitretin in a real-world setting."

Journal • Dermatology • Immunology • Psoriasis • Psychiatry

Cross-spectrum efficacy of spesolimab in IL-36-mediated dermatoses: a 'case study. (PubMed, J Dermatolog Treat) - "A 15-year-old female with ERASPEN-confirmed GPP developed hydroxychloroquine-induced AGEP (EuroSCAR score = 7) despite wild-type IL36RN and CARD14...Acitretin provided no benefit, and cyclosporine (150 mg/day) produced only transient improvement before relapse...Spesolimab produced rapid and durable control of IL-36-driven AGEP independent of IL36RN mutation status. These findings support IL-36 receptor blockade as a targeted therapeutic option for refractory AGEP and further position AGEP and GPP along a shared IL-36-mediated disease spectrum."

Journal • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Eruptive Seborrheic Keratoses Following Hpv Vaccination During Ixekizumab Therapy for Psoriasis: A Case Report and Literature Review. (PubMed, Clin Cosmet Investig Dermatol) - "We report the case of a 37-year-old female with psoriasis who, after achieving stable disease control on ixekizumab, developed widespread eruptive brown macules, patches, and papules within one month of receiving a quadrivalent HPV vaccine...The lesions faded following oral acitretin therapy...We discuss potential mechanisms, propose clinical management considerations, and provide insights that may inform future research and clinical practice. The ultimate aim is to contribute to the refinement of guidelines on vaccination in patients receiving biologic therapy for psoriasis, ensuring both therapeutic efficacy and patient safety."

Journal • Dermatology • Immunology • Oncology • Psoriasis • IL17A

Clinical Features and Long-Term Outcomes in 109 Pediatric Generalized Pustular Psoriasis. (PubMed, Dermatology) - "PGPP exhibits a trend toward flare decrease with age, yet recurrence remains common. Earlier onset age may be associated with higher flare frequency. At present, biologic agents are the main treatment. These findings provide new insights into PGPP."

Journal • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Pediatrics • Psoriasis • Psoriatic Arthritis • Pustular Psoriasis • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies

Transcriptomic landscape of generalized pustular psoriasis before and after acitretin/glucocorticoids treatment. (PubMed, Clin Exp Med) - "Combined use of glucocorticoids further reduces the expression of genes related to immune cell chemotaxis and activation. Key genes from these pathways are potential targets for developing novel treatment of GPP."

Journal • Dermatology • Immunology • Inflammation • Psoriasis • Pustular Psoriasis • CD14 • CRP • IL1B

A prospective, observational study on the epidemiology, disease characteristics and treatment outcomes for generalized pustular psoriasis in India. (PubMed, Clin Exp Dermatol) - "In resource-limited settings, early trigger identification and personalized treatment can optimize GPP outcomes. Conventional agents like methotrexate, acitretin and cyclosporine remain effective and affordable alternatives to biologics for short-term disease control."

Journal • Observational data • Dermatology • Endocrine Disorders • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Psoriasis • Pustular Psoriasis

Highlights of the Brazilian Society of Dermatology's Brazilian Consensus on Psoriasis. (PubMed, An Bras Dermatol) - "The updated treatment algorithm used experts' responses through the Delphi method and, among other modifications, removed acitretin from the plaque psoriasis treatment sequence, defined treatment lines for choosing immunobiologicals in both adult and pediatric populations, and included spesolimab and cyclosporine as first-line treatments for generalized pustular psoriasis. Finally, the new Consensus addresses the place of small molecule inhibitors in the algorithm and discusses future treatment options for plaque psoriasis."

Journal • Dermatology • Immunology • Pediatrics • Psoriasis • Pustular Psoriasis • Rheumatology

Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma (ASH 2024) - "Methotrexate (MTX) was used sequentially to either address MAR or as a maintenance strategy post-moga once blood CR was achieved...Five out of 10 patients received combotx, with 3/5 MTX, 1/5 MTX + TSEBT, and 1/5 acitretin...Retreatment with moga was well tolerated, even in patients with prior MAR. Prospective studies are needed to assess outcomes with combotx and moga retreatment."

Combination therapy • IO biomarker • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CCR4